A Hasman and S Holm have evaluated in a recent article in this journal 1 the arguments in favour and against the preventive use of an antinicotine vaccine. This has been a timely article in view of the fact that at least three companies are in advanced stages of clinical trials.
The authors refer to the beneficial effects of nicotine in inflammatory bowel disease 2 and state that ''Vaccinating a child against nicotine will not only prevent smoking but also restrict therapeutic options in later life''. We think the second part of this statement has so far not been experimentally verified and is less obvious than it may seem.
It is certainly true, that the antinicotine antibodies elicited by the antinicotine vaccine retain the nicotine molecules after challenge, as shown in numerous animal models. 3 The vicious circle at the centre of addiction is based on stimulation and instant gratification and the vaccine studies have therefore focused on the fate of the nicotine molecule immediately after nicotine challenge. The interaction of nicotine with the antibody is, however, reversible and the long term fate of the nicotine molecule and its metabolites have not been so well investigated. Despite UNOS objections, it is difficult to pinpoint who is harmed by unpaid solicitation of organs. Those on transplant waiting lists have few grounds for complaint, as the organs obtained from direct solicitation would not have been available otherwise. In such cases, the incremental increase in organ supply occurs after direct engagement with donors. At no point is an organ ''taken away'' from a transplant candidate, as there is no time in which the organ enters the wider UNOS distribution pool.
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Moreover, presuming that all transplantable organs should be relegated to UNOS belies the established practice of directed donation, explicit in the Uniform Anatomical Gift Act, 2 whereby an organ is obtained from a donor known personally by the recipient. 3 The existence of this mutual, prior relationship solely distinguishes directed donation from direct solicitation. Encouraging the former but not the latter hangs a good deal of moral weight on this criterion, which seems unsupportable given the life or death outcomes under consideration.
UNOS also recognises that it takes money to promote one's cause, so wealthier individuals will inevitably-and unfairly-enjoy greater success in contacting prospective donors. 4 Unfortunately, this line of reasoning fails to explain why wealthier individuals should rationally forgo pursuit of life improving options they can afford but which others cannot. It is especially incongruous with today's ''ability to pay'' medical system. Recourse to these exclusionary costs selectively ignores identical problems plaguing the rest of US healthcare.
Reflexive deference to the status quo is ultimately undesirable. If indeed no one is harmed by direct organ solicitation, then its recent success should be reassuring to members of the transplantation community. It should also be a wake up call to UNOS, which apparently has ample room to improve its own procurement initiatives.
Incorporation of more intimate strategies beyond rote rehearsal of depressing statistics is probably a good first step and the likely comparative advantage-and appeal-of direct solicitation. 
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